Target intelligence / Profile preview

Alpha-amylase (AMY)

Target
AMY
Molecular classification
Enzyme
01

Overview

Alpha-amylase is a key digestive enzyme responsible for the hydrolysis of alpha-1,4-glycosidic bonds in complex carbohydrates, such as dietary starch and glycogen, into simpler sugars like maltose and dextrins [6, 8]. The fungal variant, often referred to as fungal diastase and typically derived from Aspergillus oryzae, is widely used in clinical medicine as a digestive aid [2, 5]. It serves as an enzyme replacement therapy for individuals suffering from pancreatic insufficiency, chronic dyspepsia, or other malabsorption syndromes where the body's natural production of amylase is insufficient [5, 13]. By facilitating the breakdown of starch in the gastrointestinal tract, fungal diastase helps alleviate symptoms of indigestion, including bloating, flatulence, and abdominal fullness [11, 14]. In addition to its role as a therapeutic supplement, alpha-amylase is a pharmacological target for inhibitors like acarbose, which are used to manage type 2 diabetes by slowing the digestion of carbohydrates and reducing postprandial blood glucose spikes [11, 16]. The enzyme is active across a broad pH range, making it effective in various parts of the digestive tract, including the mouth and stomach [16]. Therapeutic use of fungal diastase is generally safe, though potential side effects include gastrointestinal distress and rare allergic reactions to fungal proteins [7, 11].

Other names
Fungal diastaseDiastase1,4-alpha-D-glucan glucanohydrolaseFungal alpha-amylaseAspergillus oryzae alpha-amylaseTaka-amylase A
02

Mechanism of action

Hydrolysis of alpha-1,4-glycosidic linkages in starch and glycogen; competitive inhibition of enzymatic activity to slow carbohydrate absorption and reduce postprandial glucose spikes.

03

Biological functions

Carbohydrate metabolismDigestion
04

Disease associations

Pancreatic insufficiencyDyspepsiaMalabsorption syndromeIndigestionType 2 diabetes
05

Safety considerations

Hypersensitivity to fungal proteinsGastrointestinal irritation (cramps, diarrhea)Potential for decreased efficacy of alpha-glucosidase inhibitorsRisk of acute pancreatitis exacerbation
06

Interacting drugs

Acarbose

3 more in the full profile.

07

Biomarkers

Serum amylase levelsFecal elastaseBreath hydrogen testStarch tolerance test

Beyond the preview

Go deeper on Alpha-amylase (AMY).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-amylase (AMY).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call